Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (18) 18
humans (12) 12
female (11) 11
male (11) 11
abridged index medicus (10) 10
middle aged (10) 10
cardiac & cardiovascular systems (9) 9
aged (8) 8
patients (8) 8
stroke (8) 8
medicine, general & internal (7) 7
mortality (7) 7
atrial fibrillation (5) 5
cardiology (5) 5
clinical trials (5) 5
coronary vessels (5) 5
implantation (5) 5
infarction (5) 5
myocardial infarction (5) 5
safety (5) 5
therapy (5) 5
analysis (4) 4
anticoagulants (4) 4
coronary artery (4) 4
follow-up studies (4) 4
heart attacks (4) 4
heart diseases (4) 4
motivation (4) 4
prospective studies (4) 4
acute coronary syndromes (3) 3
aged, 80 and over (3) 3
angioplasty (3) 3
anticoagulants - therapeutic use (3) 3
cardiac arrhythmia (3) 3
cardiovascular disease (3) 3
cerebral infarction (3) 3
clinical medicine (3) 3
clinical outcomes (3) 3
clopidogrel (3) 3
consortia (3) 3
coronary artery disease (3) 3
death (3) 3
defibrillators (3) 3
drug therapy (3) 3
efficacy (3) 3
electrocardiography (3) 3
europe - epidemiology (3) 3
heart (3) 3
heart failure (3) 3
heart-failure (3) 3
implants, artificial (3) 3
internal medicine (3) 3
intervention (3) 3
medical colleges (3) 3
metaanalysis (3) 3
percutaneous coronary intervention (3) 3
platelet aggregation inhibitors - administration & dosage (3) 3
prosthesis (3) 3
randomization (3) 3
revascularization (3) 3
stenosis (3) 3
stents (3) 3
task-force (3) 3
thrombosis (3) 3
transluminal angioplasty (3) 3
treatment outcome (3) 3
adult (2) 2
animals (2) 2
anticoagulation (2) 2
arrhythmias, cardiac - therapy (2) 2
biodegradable polymer (2) 2
biomarkers (2) 2
bleeding (2) 2
blood platelets (2) 2
cardiac patients (2) 2
cardiomyopathy (2) 2
cardiovascular diseases (2) 2
clinical-trials (2) 2
coagulation (2) 2
coronary artery disease - drug therapy (2) 2
defibrillators, implantable (2) 2
design (2) 2
devices (2) 2
drug delivery (2) 2
drug therapy, combination (2) 2
durable polymer (2) 2
dysfunction (2) 2
echocardiography (2) 2
edoxaban (2) 2
ejection (2) 2
electric countershock - methods (2) 2
fibrillation (2) 2
guidelines (2) 2
heart beat (2) 2
hemorrhage - chemically induced (2) 2
hemorrhage - epidemiology (2) 2
hospitals (2) 2
implantable cardioverter defibrillator (2) 2
implants (2) 2
magnetic resonance imaging (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial
by Lincoff, A Michael, Prof and Mehran, Roxana, Prof and Povsic, Thomas J, MD and Zelenkofske, Steven L, DO and Huang, Zhen, MS and Armstrong, Paul W, Prof and Steg, P Gabriel, Prof and Bode, Christoph, Prof and Cohen, Mauricio G, MD and Buller, Christopher, Prof and Laanmets, Peep, MD and Valgimigli, Marco, MD and Marandi, Toomas, MD and Fridrich, Viliam, MD and Cantor, Warren J, MD and Merkely, Bela, Prof and Lopez-Sendon, Jose, Prof and Cornel, Jan H, MD and Kasprzak, Jaroslaw D, Prof and Aschermann, Michael, Prof and Guetta, Victor, Prof and Morais, Joao, MD and Sinnaeve, Peter R, Prof and Huber, Kurt, Prof and Stables, Rod, DM and Sellers, Mary Ann, MSN and Borgman, Marilyn, BSN and Glenn, Lauren, MS and Levinson, Arnold I, Prof and Lopes, Renato D, MD and Hasselblad, Vic, Prof and Becker, Richard C, Prof and Alexander, John H, Prof and REGULATE-PCI Investigators
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10016, pp. 349 - 356
Summary Background REG1 is a novel anticoagulation system consisting of pegnivacogin, an RNA aptamer inhibitor of coagulation factor IXa, and anivamersen, a... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | REVASCULARIZATION | METAANALYSIS | EFFICACY | SAFETY | THROMBOSIS | RNA APTAMERS | ANTIBODY | COAGULATION | PHARMACODYNAMICS | INHIBITORS | Recombinant Proteins - therapeutic use | Hemorrhage - epidemiology | Hirudins | Humans | Middle Aged | Europe - epidemiology | Anticoagulants - therapeutic use | Aptamers, Nucleotide - therapeutic use | Male | Early Termination of Clinical Trials | Drug Hypersensitivity - epidemiology | Factor IXa - antagonists & inhibitors | Coagulants - administration & dosage | Female | Aged | Peptide Fragments - therapeutic use | North America - epidemiology | Oligonucleotides - administration & dosage | Percutaneous Coronary Intervention | Transluminal angioplasty | Clinical trials | Medical colleges | Anticoagulants (Medicine) | Hospitals | RNA | Anticoagulants | Stroke | Heart attacks | Heart surgery | Angioplasty | Mortality | Cardiovascular disease | Thrombosis | Clinical outcomes | Coronary vessels | Biomarkers | Patient safety | Cardiology | Acute coronary syndromes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial
by Goette, Andreas, Prof and Merino, Jose L, Prof and Ezekowitz, Michael D, Prof and Zamoryakhin, Dmitry, MD and Melino, Michael, PhD and Jin, James, PhD and Mercuri, Michele F, MD and Grosso, Michael A, MD and Fernandez, Victor, BS and Al-Saady, Naab, MD and Pelekh, Natalya, MD and Merkely, Bela, Prof and Zenin, Sergey, MD and Kushnir, Mykola, MD and Spinar, Jindrich, Prof and Batushkin, Valeriy, Prof and de Groot, Joris R, MD and Lip, Gregory Y H, Prof and ENSURE-AF Investigators and ENSURE-AF investigators
Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10055, pp. 1995 - 2003
Summary Background Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and systemic embolism in patients with atrial fibrillation... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | ORAL ANTICOAGULANTS | Stroke - prevention & control | Prospective Studies | Atrial Fibrillation - therapy | Humans | Middle Aged | Electric Countershock | Warfarin - adverse effects | Anticoagulants - therapeutic use | Enoxaparin - therapeutic use | Thiazoles - therapeutic use | Anticoagulants - adverse effects | Enoxaparin - adverse effects | Thiazoles - adverse effects | Warfarin - therapeutic use | Factor Xa Inhibitors - therapeutic use | Pyridines - adverse effects | Thromboembolism - prevention & control | Factor Xa Inhibitors - adverse effects | Aged | Hemorrhage - chemically induced | Pyridines - therapeutic use | Stroke (Disease) | Medical colleges | Warfarin | Atrial fibrillation | Clinical trials | Product development | Electric countershock | Cardiology | Public finance | Cardiac arrhythmia | Anticoagulants | Stroke | Drug therapy | Coagulation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE)
by Healey, Jeff S, Dr and Hohnloser, Stefan H, MD and Glikson, Michael, Prof and Neuzner, Jorg, MD and Mabo, Phillipe, Prof and Vinolas, Xavier and Kautzner, Josef, Prof and O'Hara, Gilles, MD and VanErven, Lieselot, MD and Gadler, Fredrik, MD and Pogue, Janice, PhD and Appl, Ursula, BSBME and Gilkerson, Jim, DVM and Pochet, Thierry, PhD and Stein, Kenneth M, MD and Merkely, Bela, Prof and Chrolavicius, Susan, BA and Meeks, Brandi, MEng and Foldesi, Csaba, MD and Thibault, Bernard, MD and Connolly, Stuart J, Prof and Shockless IMPLant Evaluation SIMPL and Shockless IMPLant Evaluation [SIMPLE] investigators
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9970, pp. 785 - 791
Summary Background Defibrillation testing by induction and termination of ventricular fibrillation is widely done at the time of implantation of implantable... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | THRESHOLD | AMIODARONE | INSERTION | THERAPY | EFFICACY | HEART-FAILURE | PREVENTION | TIME | DYSFUNCTION | REGISTRY | Single-Blind Method | Postoperative Complications - etiology | Prognosis | Arrhythmias, Cardiac - mortality | Arrhythmias, Cardiac - therapy | Risk Assessment | Humans | Middle Aged | Electric Countershock - mortality | Male | Postoperative Complications - mortality | Ventricular Fibrillation - etiology | Defibrillators, Implantable | Patient Safety | Female | Prosthesis Implantation - methods | Prosthesis Implantation - mortality | Heart Failure - etiology | Electric Countershock - methods | Defibrillators | Implants, Artificial | Prosthesis | Muscle contraction | Abnormalities | Heart failure | Cardiac arrhythmia | Transplants & implants | Mortality | Clinical medicine | Cardiology | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial
by Sibbing, Dirk and Aradi, Dániel and Aradi, Daniel and Jacobshagen, Claudius and Gross, Lisa and Trenk, Dietmar and Geisler, Tobias and Orban, Matthias and Orban, Martin and Hadamitzky, Martin and Merkely, Béla and Kiss, Róbert Gábor and Komócsi, András and Dézsi, Csaba A and Dézsi, Csaba András and Dézsi, András Döme and Holdt, Lesca and Felix, Stephan and Felix, Stephan B and Parma, Zofia and Parma, Radoslaw and Klopotowski, Mariusz and Schwinger, Robert and Schwinger, Robert H G and Rieber, Johannes and Huber, Kurt and Neumann, Franz-Josef and Koltowski, Lukasz and Mehilli, Julinda and Huczek, Zenon and Massberg, Steffen and Lesiak, Maciej and Komosa, Anna and Kowara, Michal and Rymuza, Bartosz and Malek, Lukasz and Veress, Gábor and Lux, Árpád and Papp, Judit and Kovács, Andrea and Amer, Sayour and Ruzsa, Zoltán and Róna, Szilárd and Ili, Renáta and Ungi, Imre and Nagy, Ferenc and Zweiker, Robert and Tóth-Gayor, Gábor and Haller, Paul and von Scheidt, Wolfgang and Blüthgen, Andreas and Leggewie, Stefan and Kreider-Stempfle, Hans Ulrich and Remp, Thomas and Kara, Kaffer and Mügge, Andreas and Wutzler, Alexander and Fichtlscherer, Stephan and Zeiher, Andreas M and Seeger, Florian and Hinterseer, Martin and König, Andreas and Lederle, Susanne and Czepluch, Frauke and Maier, Lars and Schillinger, Wolfgang and Sossalla, Samuel and Hummel, Astrid and Karakas, Mahir and Sydow, Karsten and Rudolph, Tanja and Halbach, Marcel and Gori, Tommaso and Münzel, Thomas and May, Andreas and Gerstenberg, Carsten-Manuel and Pilecky, David and Deichstetter, Markus and Kääb, Stefan and Löw, Anja and Sattler, Stefan and Deuschl, Sabine and Teupser, Daniel and Mudra, Harald and Räder, Thomas and Schütz, Torsten and Vahldiek, Felix and Divchev, Dimitar and Ince, Hüseyin and Nienaber, Christoph A and Radunski, Henning and Boekstegers, Peter and Horstkotte, Jan and Mueller, Ralf and Müller, Karin and Rasp, Oliver and TROPICAL-ACS Investigators
The Lancet, ISSN 0140-6736, 10/2017, Volume 390, Issue 10104, pp. 1747 - 1757
Current guidelines recommend potent platelet inhibition with prasugrel or ticagrelor for 12 months after an acute coronary syndrome managed with percutaneous... 
ELUTING STENTS | MEDICINE, GENERAL & INTERNAL | CLOPIDOGREL | THERAPY | TICAGRELOR | TREATMENT PATTERNS | PRASUGREL | DIPHOSPHATE RECEPTOR INHIBITOR | OUTCOMES | MYOCARDIAL-INFARCTION PATIENTS | PLATELET REACTIVITY | Myocardial Infarction - epidemiology | Acute Coronary Syndrome - epidemiology | Drug Administration Schedule | Hemorrhage - epidemiology | Humans | Middle Aged | Europe - epidemiology | Male | Prasugrel Hydrochloride - adverse effects | Ticlopidine - analogs & derivatives | Platelet Aggregation Inhibitors - administration & dosage | Platelet Function Tests | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Acute Coronary Syndrome - therapy | Clopidogrel | Female | Stroke - epidemiology | Hemorrhage - chemically induced | Prasugrel Hydrochloride - administration & dosage | Drug Monitoring | Percutaneous Coronary Intervention | Platelet Aggregation Inhibitors - adverse effects | Transluminal angioplasty | Care and treatment | Coronary heart disease | Cardiac patients | Analysis | Anticoagulants | Heart attacks | Blood platelets | Angioplasty | Clinical trials | Acute coronary syndromes | Drug therapy | Patients | Clinical outcomes | Myocardial infarction | Intervention | Medical services | Bleeding | Consortia | Randomization | Motivation | Inhibition | Cerebral infarction | Stroke | Test procedures | Health risks | Thrombosis | Coronary vessels | Biomarkers | Infarction | Cardiovascular diseases | Platelets
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial
by Zaman, Azfar and de Winter, Robbert J and Kogame, Norihiro and Chang, Chun Chin and Modolo, Rodrigo and Spitzer, Ernest and Tonino, Pim and Hofma, Sjoerd and Zurakowski, Aleksander and Smits, Pieter C and Prokopczuk, Janusz and Moreno, Raul and Choudhury, Anirban and Petrov, Ivo and Cequier, Angel and Kukreja, Neville and Hoye, Angela and Iniguez, Andrés and Ungi, Imre and Serra, Antonio and Gil, Robert J and Walsh, Simon and Tonev, Gincho and Mathur, Anthony and Merkely, Bela and Colombo, Antonio and Ijsselmuiden, Sander and Soliman, Osama and Kaul, Upendra and Onuma, Yoshinobu and Serruys, Patrick W and TALENT Trial Investigators and TALENT trial investigators
The Lancet, ISSN 0140-6736, 03/2019, Volume 393, Issue 10175, pp. 987 - 997
Supraflex is a sirolimus-eluting stent with a biodegradable polymer coating and ultra-thin struts. We aimed to compare Supraflex with the standard of care,... 
NON-INFERIORITY | DEFINITION | LEADERS | MEDICINE, GENERAL & INTERNAL | BIODEGRADABLE POLYMER | REVASCULARIZATION | XIENCE | DURABLE POLYMER | Clinical trials | Analysis | Myocardial infarction | Surgical implants | Heart attacks | Sirolimus | Biodegradability | Stenosis | Drug delivery | Chromium alloys | Coatings | Clinical outcomes | Randomization | Motivation | Atherosclerosis | Implants | Electrocardiography | Safety | Polymers | Lesions | Thromboembolism | Cardiology | Stents | Biodegradation | Coronary artery | Alloys | Implantation | Patients | Thrombosis | Composite materials | Arteriosclerosis | Coronary vessels | Infarction | Polymer coatings | Coating | Veins & arteries
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Prediction of mortality benefit based on periodic repolarisation dynamics in patients undergoing prophylactic implantation of a defibrillator: a prospective, controlled, multicentre cohort study
by Bauer, Axel and Klemm, Mathias and Rizas, Konstantinos D and Hamm, Wolfgang and von Stülpnagel, Lukas and Dommasch, Michael and Steger, Alexander and Lubinski, Andrzej and Lubinski, Andrezej and Flevari, Panayota and Flevari, Panagiota and Harden, Markus and Friede, Tim and Kääb, Stefan and Merkely, Béla and Merkely, Bela and Sticherling, Christian and Willems, Rik and Huikuri, Heikki and Malik, Marek and Schmidt, Georg and Zabel, Markus and Perge, Peter and Sallo, Zoltan and Szeplaki, Gabor and Lüthje, Lars and Schlögl, Simon and Haarmann, Helge and Bergau, Leonard and Seegers, Joachim and Hasenfuß, Gerd and Munoz-Exposito, Pascal and Tichelbäcker, Tobias and Kirova, Aleksandra and Hnatkova, Katerina and Vos, Marc and Willich, Stefan N and Reinhold, Thomas and Vandenberk, Bert and Klinika, Magdalena and Toplice, Krapinske and Katsimardos, Andreas and Katsaras, Dimitrios and Hatala, Robert and Svetlosak, Martin and Kuczejko, Tomasz and Hansen, Jim and Conen, David and Milosrdnice, Sestre and Pavlović, Nikola and Manola, Šime and Vinter, Ozren and Benko, Ivica and Tuinenburg, Anton and Meyer-Zürn, Christine and Eick, Christian and Hastrup, Jesper and Brugada, Josep and Arbelo, Elena and Kaliska, Gabriela and Martinek, Jozef and Sinner, Moritz F and Vdovin, Nikolay and Cygankiewicz, Iwona and Ptaszynski, Pawel and Kaczmarek, Krzysztof and Poddebska, Izabela and Iovev, Svetoslav and Novotný, Tomáš and Kozak, Milan and Kenttä, Tuomas and Pelli, Ari and Kasprzak, Jaroslaw D and Qavoq, Dariusz and Brusich, Sandro and Avdovic, Ervin and Klasan, Marina and Galuszka, Jan and Taborsky, Milos and Velchev, Vasil and Dissmann, Rüdiger and Guzik, Przemysław and Bimmel, Dieter and Lieberz, Christiane and Stefanow, Stefan and Rüb, Norman and Wolpert, Christian and Maier, Lars S and Behrens, Steffen and Jurisic, Zrinka and Braunschweig, Frieder and Blaschke, Florian and Pieske, Burkert and Bakotic, Zoran and Anic, Ante and Schwinger, Robert H.G and Platonov, Pyotr and EU-CERT-ICD Investigators and EU-CERT-ICD investigators
The Lancet, ISSN 0140-6736, 10/2019, Volume 394, Issue 10206, pp. 1344 - 1351
A small proportion of patients undergoing primary prophylactic implantation of implantable cardioverter defibrillators (ICDs) experiences malignant... 
PREVENTION | MEDICINE, GENERAL & INTERNAL | RISK | DEATH | CARDIOVERTER-DEFIBRILLATOR | SUDDEN | Austria | Mortality | Analysis | Germany | Heart | Heart failure | Cardiac arrhythmia | Adjustment | Cardiomyopathy | Implantation | Patients | Studies | Consortia | Reduction | Defibrillators | Dynamics | Dynamic stability | Predictions | Clinical medicine | Ventricle | Ejection
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial
by Vranckx, Pascal and Valgimigli, Marco and Jüni, Peter and Hamm, Christian and Steg, Philippe Gabriel and Steg, Gabriel and Heg, Dik and van Es, Gerrit Anne and McFadden, Eugene P and McFadden, Eugene and Onuma, Yoshinobu and van Meijeren, Cokky and Chichareon, Ply and Benit, Edouard and Möllmann, Helge and Janssens, Luc and Ferrario, Maurizio and Moschovitis, Aris and Zurakowski, Aleksander and Dominici, Marcello and Van Geuns, Robert Jan and Huber, Kurt and Slagboom, Ton and Serruys, Patrick and Serruys, Patrick W and Windecker, Stephan and Abdellaoui, Mohamed and Adlam, David and Akin, Ibrahim and Albarran Gonzalez-Trevilla, Agustin and Almeida, Manuel and Alves Lemos Neto, Pedro and Aminian, Adel and Anderson, Richard and Andreae, Rick and Angioi, Michael and Asano, Taku and Barbato, Emanuele and Barlis, Peter and Barraud, Pascal and Bertrand, Olivier and Beygui, Farzin and Bolognese, Leonardo and Botelho, Roberto and Bouwman, Coby and Bressers, Marco and Brunel, Philippe and Buszman, Pawel and Buysschaert, Ian and Canas da Silva, Pedro and Carrie, Didier and Cequier, Angel and Chin Chang, Chun and Chowdhary, Saqib and Collet, Carlos and Colombo, Antonio and Cotton, James and Cruz Ferreira, Rui and Curello, Salvatore and Curzen, Nick and de Bot, Judith and de Vreede, Tone and Delle Karth, Georg and Dijksma, Lynn and Édes, István and Eeckhout, Eric and Eitel, Ingo and Faluközy, József and Fath-Ordoubadi, Farzin and Fontos, Geza and Francisco Diaz, Jose and Freitas Quintella, Edgard and Frey, Bernhard and Friedrich, Guy and Galasko, Gavin and Galuszka, Grzegorz and Gama Ribeiro, Vasco and Garg, Scot and Gargiulo, Giuseppe and Geisler, Tobias and Gelev, Valeri and Ghandilyan, Art and Goicolea, Javier and Gori, Tommaso and Gragnano, Felice and Guimarães, Ana and Haude, Michael and Heijke, Pieter and Hernández Antolin, Rosa Ana and Hildick-Smith, David and Hillen, Dorien and Hoekman, Ina and Hofma, Sjoerd and Holmvang, Lene and Hoole, Stephen and Horváth, Iván and Hugense, Annemarie and Ibrahim, Karim and Iñiguez, Andres and Isaaz, Karl and ... and GLOBAL LEADERS Investigators
The Lancet, ISSN 0140-6736, 09/2018, Volume 392, Issue 10151, pp. 940 - 949
We hypothesised that ticagrelor, in combination with aspirin for 1 month, followed by ticagrelor alone, improves outcomes after percutaneous coronary... 
DEFINITIONS | MEDICINE, GENERAL & INTERNAL | BIODEGRADABLE POLYMER | METAANALYSIS | DUAL-ANTIPLATELET THERAPY | MYOCARDIAL-INFARCTION | ACADEMIC RESEARCH CONSORTIUM | CLINICAL-TRIALS | ACUTE CORONARY SYNDROMES | DURABLE POLYMER | INTERVENTION | Myocardial Infarction - mortality | Purinergic P2Y Receptor Antagonists - administration & dosage | Humans | Middle Aged | Male | Coronary Artery Disease - drug therapy | Coronary Artery Disease - mortality | Adenosine - administration & dosage | Ticlopidine - analogs & derivatives | Aspirin - administration & dosage | Drug-Eluting Stents - adverse effects | Coronary Angiography | Adenosine - analogs & derivatives | Platelet Aggregation Inhibitors - administration & dosage | Intention to Treat Analysis | Ticlopidine - administration & dosage | Clopidogrel | Female | Aged | Myocardial Infarction - prevention & control | Drug Therapy, Combination | Ticagrelor | Percutaneous Coronary Intervention | Aggregation | Blood platelets | Analysis | Myocardial infarction | Intervention | Therapy | Surgical implants | Heart attacks | Disorders | Cardiovascular disease | Drug delivery | Bleeding | Subgroups | Consortia | Randomization | Motivation | Implants | Heart diseases | Stents | Drug dosages | Aspirin | Stroke | Mortality | Coronary artery | Implantation | Coronary artery disease | Patients | Coronary vessels | Fatalities | Infarction | Acute coronary syndromes | Biosensors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Full-Body MRI in Patients With an Implantable Cardioverter-Defibrillator: Primary Results of a Randomized Study
by Gold, Michael R and Sommer, Torsten and Schwitter, Juerg and Al Fagih, Ahmed and Albert, Timothy and Merkely, Béla and Peterson, Michael and Ciuffo, Allen and Lee, Sung and Landborg, Lynn and Cerkvenik, Jeffrey and Kanal, Emanuel and Evera MRI Study Investigators
Journal of the American College of Cardiology, ISSN 0735-1097, 06/2015, Volume 65, Issue 24, pp. 2581 - 2588
Abstract Background Magnetic resonance imaging (MRI) of patients with conventional implantable cardioverter-defibrillators (ICD) is contraindicated. Objectives... 
magnetic resonance imaging | implantable cardioverter-defibrillator | CARDIAC & CARDIOVASCULAR SYSTEMS | TASK-FORCE | HEART-FAILURE | GUIDELINES | DEVICES | ICD | Defibrillators, Implantable - adverse effects | Follow-Up Studies | Humans | Magnetic Resonance Imaging - adverse effects | Middle Aged | Cardiovascular Diseases - therapy | Magnetic Resonance Imaging - methods | Male | Electric Countershock - adverse effects | Electric Countershock - instrumentation | Internationality | Cardiovascular Diseases - epidemiology | Female | Aged | Cardiovascular Diseases - diagnosis | Electric Countershock - methods | Heart beat | Defibrillators | Implants, Artificial | Prosthesis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Clinical Outcomes With a Repositionable Self-Expanding Transcatheter Aortic Valve Prosthesis: The International FORWARD Study
by Grube, Eberhard and Van Mieghem, Nicolas M and Bleiziffer, Sabine and Modine, Thomas and Bosmans, Johan and Manoharan, Ganesh and Linke, Axel and Scholtz, Werner and Tchétché, Didier and Finkelstein, Ariel and Trillo, Ramiro and Fiorina, Claudia and Walton, Antony and Malkin, Christopher J and Oh, Jae K and Qiao, Hongyan and Windecker, Stephan and Grube, Eberhard and Windecker, Stephan and Bosmans, Johan and Bleiziffer, Sabine and Manoharan, Ganesh and Modine, Thomas and Van Mieghem, Nicolas and Sinhal, Ajay and Gooley, Robert and Walton, Tony and Yong, Gerald and Bosmans, Johan and Webb, John and Chu, Michael and Radhakrishnan, Sam and Dager, Antonio and Branny, Marian and Tchetche, Didier and Modine, Thomas and Teiger, Emmanuel and Chevalier, Bernard and Himbert, Dominique and Schymik, Gerhard and Zeus, Tobias and Jensen, Christoph and Rassaf, Tienush and Fichtlscherer, Stephan and Nickenig, Georg and Linke, Axel and Bleiziffer, Sabine and Kempfert, Jörg and Scholtz, Werner and Harnath, Axel and Strasser, Ruth and Frerker, Christian and Spargias, Konstantinos and Merkely, Béla Peter and Finkelstein, Ariel and Tamburino, Corrado and Colombo, Antonio and Petronio, Anna Sonia and Fiorina, Claudia and Bedogni, Francesco and Amoroso, Giovanni and van der Heijden, Jan and Van Mieghem, Nicolas and Tonino, Pim and Echeverria Beliz, Pedro and Witkowski, Adam and Gama Ribeiro, Vasco and Al Abdullah, Moheeb and Weich, Hellmuth and Trillo, Ramiro and Hernández García, José Maria and Moris, Cesar and Jönsson, Anders Lars and Malkin, Christopher J and Khogali, Saib and Hildick-Smith, David and Manoharan, Ganesh and FORWARD Study Investigators
Journal of the American College of Cardiology, ISSN 0735-1097, 08/2017, Volume 70, Issue 7, pp. 845 - 853
Background Clinical outcomes in large patient populations from real-world clinical practice with a next-generation self-expanding transcatheter aortic valve... 
transcatheter aortic valve replacement | degenerative valve | aortic stenosis | REPLACEMENT | SURGERY | INTERMEDIATE-RISK PATIENTS | CARDIAC & CARDIOVASCULAR SYSTEMS | STENOSIS | THERAPY | IMPLANTATION | BIOPROSTHESIS | DEEMED EXTREME RISK | END-POINT DEFINITIONS | REGISTRY | Severity of Illness Index | Multidetector Computed Tomography | Echocardiography | Prospective Studies | Survival Rate - trends | Follow-Up Studies | Global Health | Heart Valve Prosthesis | Humans | Risk Factors | Male | Treatment Outcome | Aortic Valve Stenosis - diagnosis | Prosthesis Design | Aortic Valve Stenosis - mortality | Time Factors | Aged, 80 and over | Cause of Death - trends | Female | Aortic Valve Stenosis - surgery | Transcatheter Aortic Valve Replacement - methods | Heart valve diseases | Implants, Artificial | Prosthesis | Patient outcomes | Prostheses | Stroke | Mortality | Stenosis | Risk | Thorax | Patients | Collaboration | Surgery | Regurgitation | Electrocardiography | Aorta | Mercury | Aortic valve
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights